The proteomic 2D-DIGE approach reveals the protein voltage-dependent anion channel 2 as a potential therapeutic target in epithelial thyroid tumours

Molecular and Cellular Endocrinology

Volumn 404, Issue , 2015, Pages 37-45

  Mato, Eugenia ^a,b   Barceló Batllori, Sílvia ^c   Orera, Irene ^d   Selva, Laia ^b   Corra, Martina ^c   González, Cintia ^a,b   Bell, Olga ^a,b   Lerma, Enrique ^e   Moral, Antonio ^e   Pérez, José Ignacio ^e   de Leiva, Alberto ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^d INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Epithelial thyroid tumours; Therapeutic target; Voltage dependent anion channel 2

Indexed keywords

BAK1 PROTEIN, HUMAN; BAX PROTEIN, HUMAN; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PHARMACOLOGY; PROTEIN BAK; PROTEIN BAX; SORAFENIB; VDAC2 PROTEIN, HUMAN; VOLTAGE DEPENDENT ANION CHANNEL 2;

ADOLESCENT; ADULT; AGED; ANALOGS AND DERIVATIVES; ARTICLE; BAK1 GENE; BAX GENE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; DRUG TARGETING; DRUG THERAPY; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETICS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METABOLISM; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; PATHOLOGY; POORLY DIFFERENTIATED THYROID CANCER; PROCEDURES; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID NEOPLASMS; TUMOR CELL LINE; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; UPREGULATION; VDAC2 GENE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALOGS AND DERIVATIVES; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; DRUG THERAPY; FEMALE; GENETICS; HUMANS; MALE; METABOLISM; METHODS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; NIACINAMIDE; PATHOLOGY; PHARMACOLOGY; PHENYLUREA COMPOUNDS; PROTEOMICS; THYROID NEOPLASMS; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; UP-REGULATION; VOLTAGE-DEPENDENT ANION CHANNEL 2; YOUNG ADULT;

EID: 84964228068     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.01.021     Document Type: Article

References (45)

1. Barcelo-Batllori S., Kalko S.G., Esteban Y., Moreno S., Carmona M.C., Gomis R. Integration of DIGE and bioinformatics analyses reveals a role of the antiobesity agent tungstate in redox and energy homeostasis pathways in brown adipose tissue. Mol. Cell. Proteomics 2008, 7:378-393.
2. Benjamin D.I., Cravatt B.F., Nomura D.K. Global profiling strategies for mapping dysregulated metabolic pathways in cancer. Cell Met 2012, 16:565-577. 10.1016/j.cmet.2012.09.013.
3. Brown J.M., Attardi L.D. The role of apoptosis in cancer development and treatment response. Nat. Rev. Cancer 2005, 5:231-237. 10.1038/nrc1560.
4. Brown L.M., Helmke S.M., Hunsucker S.W., Netea-Maier R.T., Chiang S.A., Heinz D.E., et al. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol. Carcinog 2006, 45:613-626. 10.1002/mc.20193.
5. Burlacu A.J. Regulation of apoptosis by Bcl-2 family proteins. J. Cell. Mol. Med 2003, 7:249-257. 10.1111/j.1582-4934.2003.tb00225.x.
6. Chen Y., Cairns R., Papandreou I., Koong A., Denko N.C. Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect. PLoS ONE 2009, 4:e7033. 10.1371/journal.pone.0007033.
7. Cheng E.H.Y., Sheiko T.V., Fisher J.K., Craigen W.J., Korsmeyer S.J. VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science 2003, 301:513-517. 10.1126/science.1083995.
8. Fiek C., Benz R., Roos N., Brdiczka D. Evidence for identity between the hexokinase-binding protein and the mitochondrial porin in the outer membrane of rat liver mitochondria. Biochim. Biophys. Acta 1982, 688:429-440. 10.1159/000343350.
9. Grills C., Jithesh P.V., Blayney J., Zhang S.D., Fennell D.A. Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer. PLoS ONE 2011, 6:e14635. 10.1371/journal.pone.0014635.
10. Gürtler A., Kunz N., Gomolka M., Hornhardt S., Friedl A.A., McDonald K., et al. Stain-Free technology as a normalization tool in Western blot analysis. Anal. Biochem 2013, 433:105-111. 10.1016/j.ab.2012.10.010.
11. Koren I., Raviv Z., Shoshan-Barmatz V. Downregulation of voltage-dependent anion channel-1 expression by RNA interference prevents cancer cell growth in vivo. Cancer Biol. Ther 2010, 9:1046-1052. 10.1530/ERC-13-0150.
12. Krause K., Karger S., Schierhorn A., Poncin S., Many M.C., Fuhrer D. Proteomic profiling of cold thyroid nodules. Endocrinology 2007, 148:1754-1763. 10.1210/en.2006-0752.
13. Krause K., Jessnitzer B., Fuhrer D. Proteomics in thyroid tumor research. JCEM 2009, 94:2717-2724. 10.1210/jc.2009-0308.
14. Lazarou M., Stojanovski D., Frazier A.E., Kotevski A., Dewson G., Craigen W.J., et al. Inhibition of bak activation by VDAC2 is dependent on the bak transmembrane anchor. J. Biol. Chem 2010, 285:36876-36883. 10.1074/jbc.M110.159301.
15. Leanza L., Biasutto L., Managò A., Gulbins E., Zoratti M., Szabò I. Intracellular ion channels and cancer. Front. Physiol 2013, 4(3):227. eCollection. 10.3389/fphys.2013.00227.
16. Lecocq R., Lamy F., Dumont J.E. Pattern of protein phosphorylation in intact stimulated cells: thyrotropin and dog thyroid. Eur. J. Biochem 1979, 102:147-152. 10.1111/j.1432-1033.1979.tb06274.x.
17. Linden M., Karlsson G. Identification of porin as a binding site for MAP2. Biochem. Biophys. Res. Commun 1996, 218:833-836. 10.1006/bbrc.1996.0148.
18. Maldonado E.N.1., Sheldon K.L., DeHart D.N., Patnaik J., Manevich Y., Townsend D.M., et al. Voltage-dependent anion channels modulate mitochondrial metabolism in cancer cells: regulation by free tubulin and erastin. J. Biol. Chem 2013, 288:11920-11929. 10.1074/jbc.M112.433847.
19. Mazzaferri E.L. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999, 9:421-427. 10.1089/thy.1999.9.421.
20. Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V., Pereira-Castro I., et al. Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid 2007, 17:707-715. 10.1089/thy.2007.0097.
21. Messina A., Reina S., Guarino F., De Pinto V. VDAC isoforms in mammals. Biochim. Biophys. Acta 2012, 6:466-476. 10.1016/j.bbamem.2011.10.005.
22. Moretz W.H., Gourin C.G., Terris D.J., Xia Z.S., Liu Z., Weinberger P.M., et al. Detection of papillary thyroid carcinoma with serum protein profile analysis. Arch. Otolaryngol. Head Neck Surg 2008, 134:198-202. 10.1001/archoto.2007.34.
23. Netea-Maier R.T., Hunsucker S.W., Hoevenaars B.M., Helmke S.M., Slootweg P.J., Hermus A.R., et al. Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Res 2008, 68:1572-1580. 10.1158/0008-5472.
24. Niemeier L.A., Kuffner A.H., Song C., Carty S.E., Hodak S.P., Yip L., et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer 2012, 118:2069-2077. 10.1002/cncr.26425.
25. Nikiforov Y.E., Nikiforova M.N. Molecular genetics and diagnosis of thyroid cancer. Nat. Rev. Endocrinol 2011, 30:569-580. 10.2307/1844855.
26. Pedersen P.L. Tumor mitochondria and the bioenergetics of cancer cells. Prog. Exp. Tumor Res 1978, 22:190-274. 10.1007/s10863-013-9529-5.
27. Ramirez A., Barceló-Batllori S., Martínez-Beamonte R., Navarro M.A., Surra J.C., Arnal C., et al. Proteomics and gene expression analyses of squalene-supplemented mice identify microsomal thioredoxin domain-containing protein 5 changes associated with hepatic steatosis. J Proteomics 2012, 77:27-39. 10.1016/j.jprot.2012.07.001.
28. Saccone C., Caggese C., D'Erchia A.M., Lanave C., Oliva M., Pesole G. Molecular clock and gene function. J. Mol. Evol 2003, 57:277-285. 10.1111/j.1365-3059.2006.01549.x.
29. Sampson E., Brierley J.D., Le L.W., Rotstein L., Tsang R.W. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 2007, 110:1451-1456. 10.1002/ijc.24250.
30. Schein S.J., Colombini M., Finkelstein A. Reconstitution in planar lipid bilayers of a voltage-dependent anion-selective channel obtained from Paramecium mitochondria. J. Membr. Biol 1976, 30:99-120. 10.1007/BF01869662.
31. Shimizu S., Narita M., Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999, 399:483-487. 10.1038/20959.
32. Shimizu S., Matsuoka Y., Shinohara Y., Moneda Y., Tsujimoto Y. Essential role of voltage-dependent anion channel in various forms of apoptosis in mammalian cells. J. Cell Biol 2001, 152:237-250. 10.1083/jcb.152.2.237.
33. Shinohara Y., Ishida T., Hino M., Yamazaki N., Baba Y., Terada H. Characterization of porin isoforms expressed in tumor cells. Eur. J. Biochem 2000, 267:6067-6073. 10.1046/j.1432-1327.2000.01687.
34. Simamura E., Shimada H., Hatta T., Hirai K.I. Mitochondrial voltage-dependent anion channels (VDACs) as novel pharmacological targets for anti-cancer agents. J. Bioenerg. Biomembr 2008, 40:213-217. 10.1007/s10863-008-9158-6.
35. Singhal S., Weiwrodt R., Malden L., Matzie K., Friedberg J., Amin K.M., et al. Gene expression profiling of malignant mesothelioma. Clin. Cancer Res 2003, 9:3080-3097. 10.1074/jbc.273.40.26087.
36. Sofiadis A., Becker S., Hellman U., Hultin-Rosenberg L., Dinets A., Hulchiy M., et al. Proteomic profiling of follicular and papillary thyroid tumors. Eur. J. Endocrinol 2012, 166:657-667. 10.1530/EJE-11-0856.
37. Szklarczyk D., Franceschini A., Kuhn M., Simonovic M., Roth A., Minguez P., et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 2011, 39:561-568. 10.1093/nar/gkq973.
38. Tajeddine N., Galluzzi L., Kepp O., Hangen E., Morselli E., Senovilla L., et al. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 2008, 27:4221-4232. 10.1038/onc.2008.63.
39. Tian Q., Stepaniants S.B., Mao M., Weng L., Feetham M.C., Doyle M.J., et al. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol. Cell. Proteomics 2004, 3:960-969. 10.1074/mcp.M400055-MCP200.
40. Torres-Cabala C., Bibbo M., Panizo-Santos A., Barazi H., Krutzsch H., Roberts D.D., et al. Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol 2006, 50:518-528. 10.1159/000326006.
41. Tsujimoto Y., Shimizu S. VDAC regulation by the Bcl-2 family of proteins. Cell Death Differ 2000, 7:1174-1181. 10.1038/sj.cdd.4400780.
42. Unwin R.D., Craven R.A., Harnden P., Hanrahan S., Totty N., Knowles M., et al. Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 2003, 3:1620-1632. 10.1002/pmic.200300464.
43. Wang J.X., Yu J.K., Wang L., Liu Q.L., Zhang J., Zheng S. Application of serum protein fingerprint in diagnosis of papillary thyroid carcinoma. Proteomics 2006, 6:5344-5349. 10.1002/pmic.200500833.
44. Warburg O., Dickens F., Kaiser Wilhelm-Institut fur Biologie B. The Metabolism of Tumours: Investigations from the Kaiser-Wilhelm Institute for Biology, Berlin-Dahlem 1930, Constable & Co, Ltd, London, UK.
45. Zuo H., Gandhi M., Edreira M.M., Hochbaum D., Nimgaonkar V.L., Zhang P., et al. Down-regulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. Cancer Res 2010, 70:1389-1397. 10.1158/0008-5472.